Osmind

04/30/2026

Our CEO, Lucia Huang, spoke at this week on "Psychedelics: Preparing Your Clinic." A few takeaways from her panel:

1. The strongest practices aren’t single-modality. Combining medication management, therapy, and interventional psychiatry like Spravato and TMS are what drives outcomes *and* retention.
`
2. Billing for interventional psychiatry isn’t just claims submission. Heavy prior auth and benefits verification mean revenue operations is a real function, not a checkbox.

3. For practices excited about potential future psychedelics, they need to start preparing now given the stakes will only get higher with longer and more expensive treatments.

The through-line: the practices that will succeed with psychedelic medicine are the ones treating it as a full operational build—staff training, tech, documentation and compliance—before they need it.

Grateful to Brain Futures for the invitation to be part of the conversation.

04/29/2026

Looking to lower your SPRAVATO® drug costs and streamline your practice operations?

Join our monthly SPRAVATO® office hours hosted live inside the Psychiatry Collective on May 5th at 9 am PT / 12 pm ET.

This is a dedicated space for clinicians and practice teams to get practical guidance, ask questions, and learn from experts and peers in the community.

This month’s session will cover:
•Ways to reduce SPRAVATO® drug costs through available community benefits
•Step-by-step onboarding and setup guidance
•SPRAVATO® practice management and operational best practices
•Live Q&A—bring your questions

(RSVP link in comments below) 👇

04/21/2026

Osmind is proud to collaborate with Compass Pathways to help independent psychiatry practices prepare for the potential future delivery of psychedelic medicine.

Independent practices are where most patients receive their care, but they've historically been left behind when it comes to adopting novel treatments.

This collaboration combines Osmind's deep understanding of how clinics operate with Compass's scientific expertise to inform scalable, real-world pathways for the potential delivery of novel psychedelic treatments in mental health care.

Learn more in the full press release:

04/20/2026

Saturday's executive order clears federal roadblocks that have slowed psychedelic treatments for decades. But approval (if and when it comes) doesn't equal access.

Between a federal approval and a patient receiving treatment at an independent practice, there's an operational gap that policy alone can't close. REMS compliance, drug procurement, EHR documentation standards, reimbursement, staff training: practices are largely left to figure this out on their own.

It's also where real-world evidence becomes critical. The EO specifically calls for RWE generation, and the reason is simple: clinical trials tell you what a treatment can do. Real-world data tells you how it works across the actual patient populations and practice settings where care is delivered.

This is the work we've been doing at Osmind for the last six years, alongside the 1,000+ independent psychiatry practices we serve navigating this every day. We're glad it's becoming a national priority.

04/13/2026

The business side of psychiatry doesn't come with a textbook.
That's why Brittany Albright MD, MPH, DABOM, addiction and interventional psychiatrist and founder of Sweetgrass Psychiatry is hosting a Practice Management live event this Wednesday at 9 am PT / 12 pm ET inside the Psychiatry Collective.

No slides, no lectures, just real talk with fellow clinicians.

Bring your questions on staffing, billing, scheduling, growth, workflows—or just listen in. Dr. Albright will kick things off, but the floor is open.

03/20/2026

Treatment-resistant depression doesn't have a formal DSM definition. But most psychiatrists know it when they see it—and most of them are seeing it constantly.

Osmind CMO William Sauvé, MD and medical advisor Brittany Albright MD, MPH, DABOM Albright, MD joined a Psychiatric Times panel to unpack why depression persists after multiple medication trials, and what full remission actually requires.

A few things that stood out:
→ The majority of patients with MDD in psychiatric practice meet the threshold for TRD: two or more adequate trials at appropriate dose and duration

→ Many patients who say they've "tried everything" discontinued within days. Distinguishing that from true TRD matters before changing course.

→ Residual symptoms, even with partial response, significantly increase relapse risk

→ One panelist reframed TRD as "monoamine treatment-resistant depression"; the medications are failing patients, not the other way around

Full remission, not just response, is the goal.

Watch here →https://www.psychiatrictimes.com/view/treatment-resistant-depression-residual-symptoms-and-remission

03/18/2026

Eli Lilly just launched Phase 3 trials for a GLP-1 drug in alcohol use disorder. Not diabetes. Not weight loss. Addiction.

GLP-1 receptors sit in the VTA, nucleus accumbens, insula, and prefrontal cortex, the brain regions that run reward, craving, and compulsion. In a study of 142,000+ patients published this month in Frontiers in Psychiatry, GLP-1 RA users had 75% lower odds of any substance use disorder.

William Sauvé, MD, Annette Bosworth, MD, and Brittany Albright MD, MPH, DABOM break down what psychiatrists need to know:

→ Why the addiction trial data is stronger than most clinicians realize

→ How anhedonia on GLP-1s may be a dosing problem, not a drug problem (and a ziprasidone parallel that hits close to home)

→ What low-dose tirzepatide combined with a ketogenic diet looks like in real patients

One clinician on the call shared a case: a 42-year-old woman with alcohol use disorder whose PHQ-9 dropped from the twenties to 2 in seven weeks on tirzepatide.

If you treat reinforcement dysregulation, you can't afford to outsource this drug class to primary care.

Read the full breakdown here →

Are GLP-1 agonists psychiatric drugs? The neuroscience of reward, new addiction trial data, and a dosing hypothesis that reframes anhedonia.

03/09/2026

Your most treatment-resistant patients need more options. This webinar shows you how to deliver them.

Considering VNS Therapy™ for your patients with difficult-to-treat depression? This webinar covers what happens after you decide it's the right clinical option.

Dr. Karen Giles joins Dr. Will Sauve to discuss the practical side of VNS Therapy implementation. From identifying candidates to understanding the surgical procedure and dosing, they'll walk through the essential knowledge for both new and experienced prescribers.

March 12, 2026 | 11am PT / 2pm ET

Can't make it live? Register and we'll send you the recording.
https://osmind-org.zoom.us/webinar/register/1017721267187/WN_yFgJuxNXRseiQn8KeWnvmw

Webinar selected by Osmind | Sponsored by LivaNova, PLC
More information about VNS Therapy for Difficult-to-treat Depression (DTD) is available at https://www.livanova.com/depression/en-us

The VNS Therapy™ System is indicated for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.
Important safety information is available at https://www.livanova.com/depression/en-us/hcp-safety-information

DEP-2500192

03/04/2026

The average patient in the RECOVER trial had been living with their current depressive episode for 18 years. They'd failed 13 antidepressants. Half had tried ECT.

In our latest webinar, Dr. Hamish McAllister-Williams from Newcastle University breaks down the RECOVER trial results for VNS Therapy in difficult-to-treat depression. The findings challenge how we think about treatment success:

The primary symptom endpoint missed significance - but quality of life improved meaningfully:

•Patients who failed ECT or TMS showed the strongest differential benefit

•80% of responders maintained gains at 24 months

Dr. McAllister-Williams makes a compelling case: "Treatment goals are not defined solely by symptom remission." For patients with profound, chronic treatment resistance, improvements in day-to-day function and quality of life represent genuine progress.

Watch the full webinar to learn which patients benefit most and what the durability data tells us about long-term outcomes: https://www.osmind.org/blog/evidence-for-vns-therapy

Selected by Osmind | Sponsored by LivaNova, PLC
More information about VNS Therapy for Difficult-to-treat Depression (DTD) is available at https://www.livanova.com/depression/en-us

The VNS Therapy™ System is indicated for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.

Important safety information is available at
https://www.livanova.com/depression/en-us/hcp-safety-information

DEP-2600003

03/03/2026

Your most treatment-resistant patients need more options. This webinar shows you how to deliver them.

Considering VNS Therapy™ for your patients with difficult-to-treat depression? This webinar covers what happens after you decide it's the right clinical option.

Dr. Karen Giles joins Dr. Will Sauve to discuss the practical side of VNS Therapy implementation. From identifying candidates to understanding the surgical procedure and dosing, they'll walk through the essential knowledge for both new and experienced prescribers.

March 12, 2026 | 11am PT / 2pm ET

Can't make it live? Register and we'll send you the recording.
https://osmind-org.zoom.us/webinar/register/5517664319437/WN_yFgJuxNXRseiQn8KeWnvmw #/

Webinar selected by Osmind | Sponsored by LivaNova, PLC
More information about VNS Therapy for Difficult-to-treat Depression (DTD) is available at https://www.livanova.com/depression/en-us

The VNS Therapy™ System is indicated for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.

Important safety information is available at https://www.livanova.com/depression/en-us/hcp-safety-information

DEP-2500192

02/26/2026

Five years ago, Benjamin Leopold was curled on his apartment floor with a bottle of scotch. Today he runs marathons, writes horror novels, and surfs whenever he can get to the coast.

He cycled through 10 antidepressants in 18 months. The side effects were brutal. Emotional blunting erased his personality and got mistaken for progress.

It wasn't until a psychiatrist stopped prescribing and started asking what was underneath the depression that things changed. SPRAVATO® (esketamine) gave a bird’s eye view to years of trauma.

During dissociation, Ben could finally step outside his anxiety and see himself clearly for the first time:

"That's who Ben is? Dude, you're okay, man. Look at all the stuff you've done and all the things you've been through and all the amazing people in your life."

In this episode of Psychiatry Tomorrow, Ben sits down with and to walk through the full journey—from childhood trauma, to the antidepressant carousel, to the moment he finally saw what everyone around him had seen all along.

Worth a listen/read if you've ever wondered what treatment-resistant depression actually looks like from the patient's seat.

🎧

Hear how one Spravato patient went from cycling through 10 antidepressants to building a life he loves — running marathons, writing novels, and surfing. Ben Leopold shares how the combination of deep therapeutic work and Spravato treatment finally broke through his treatment-resistant depression.

02/19/2026

For psychiatrists looking to help treatment-resistant patients while adding a profitable service line, TMS is worth a serious look.

TMS response rates run 50-60% for standard protocols. Accelerated protocols are pushing 80%+. Covered by insurance. And new devices have dropped the barrier to entry to $3,000/month with no upfront capital.

Our Chief Medical Officer, William Sauvé, MD, and Ben Spielberg wrote a guide to adding TMS to your practice. It covers:

•Patient eligibility: 4 FDA-cleared indications, common off-label uses, and CE-marked indications in Europe

• Setting realistic expectations with patients

• 8 TMS devices compared with latest available pricing, from Ampa's $3K/month portable subscription to BrainsWay's deep TMS with the broadest FDA clearances, and Nexstim's MRI-guided neuronavigation

• Deep coils vs. figure-8: efficacy data, clearances, and real trade-offs

• Financing: lease vs. purchase, third-party lenders, and Section 179 tax implications

• Billing codes, prior auth strategy, and reimbursement ranges

• Building your referral pipeline before the device even arrives

This is the guide we wish existed when practices started asking us about TMS.

Read it here →

Ready to add TMS to your practice? This guide covers patient eligibility, 2026 device pricing for 8 systems, financing, billing codes, and how to build your referral pipeline from day one.